Request Deal Involvement

Novo Holdings led a $125m Series C funding round in Hummingbird Bioscience.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

Latham & Watkins

legal advisors

Latham & Watkins

or

Principals

FRAZIER HEALTHCARE PARTNERS

bidder

FRAZIER HEALTHCARE PARTNERS

OCTAGON CAPITAL

bidder

OCTAGON CAPITAL

HERITAS CAPITAL

bidder

HERITAS CAPITAL

PUREOS BIOVENTURES

bidder

PUREOS BIOVENTURES

AMGEN INC

bidder

AMGEN INC

DROIA VENTURES

bidder

DROIA VENTURES

POLARIS PARTNERS

bidder

POLARIS PARTNERS

SK GROUP

bidder

SK GROUP

EDBI

bidder

EDBI

ALTIUM CAPITAL

bidder

ALTIUM CAPITAL

HUMMINGBIRD BIOSCIENCE

target

HUMMINGBIRD BIOSCIENCE

MORNINGSIDE VENTURE CAPITAL

bidder

MORNINGSIDE VENTURE CAPITAL

AFFINITY ASSET ADVISORS

bidder

AFFINITY ASSET ADVISORS

ALLY BRIDGE GROUP

bidder

ALLY BRIDGE GROUP

MIRAE ASSET CAPITAL CO LTD

bidder

MIRAE ASSET CAPITAL CO LTD

NOVO HOLDINGS A/S

bidder

NOVO HOLDINGS A/S

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Novo Holdings led a $125m Series C funding round in Hummingbird Bioscience.